$TGTX

TG THERAPEUTICS, INC.

TG Therapeutics is a commercial-stage biotechnology company focused on acquiring, developing and commercializing treatments for B-cell diseases. Its main commercial product is BRIUMVI, an anti-CD20 monoclonal antibody approved to treat adults with relapsing forms of multiple sclerosis. TG Therapeutics sells BRIUMVI in the United States and works with Neuraxpharm to commercialize it in certain territories outside the United States, Canada and Mexico. The company earns money from product sales and, under its commercialization agreement, receives milestone payments and royalties on sales in covered territories. Its development pipeline includes intravenous and subcutaneous ublituximab, as well as azer-cel, a donor-derived CAR T cell therapy being studied for autoimmune diseases. TG Therapeutics also operates the Next In MS platform, which supports conversations about life with multiple sclerosis. The company is headquartered in Morrisville, North Carolina.

1
0
0

No SEC Form 4 filings for $TGTX in the last 30 days.

See all $TGTX insider activity →
Low

TG Therapeutics: 3 Key Takeaways for Long-Term Investors

TG Therapeutics' executives expressed confidence in BRIUMVI's long-term growth potential, citing expanded patient reach, existing commercial infrastructure, and a long patent runway. The company has $557 million in cash and investments, with patent protection extending into the mid-2040s, providing financial flexibility for pipeline progress and share repurchases.

TG Therapeutics (TGTX) Q3 2026 Earnings Call Transcript

TG Therapeutics (TGTX) reported $1B annual revenue, highlighting progress with BRIUMVI. Key updates include seven-year clinical data, real-world evidence, and potential approvals for simplified IV dosing and self-administered subcutaneous BRIUMVI by 2028. The company also presented early results for azer-cel in progressive MS, aiming to expand its MS treatment portfolio.

TGTX sentiment & insider activity

Over the past 7 days, AlphAI's AI scored 1 news story mentioning TGTX (TG THERAPEUTICS, INC.). Coverage has skewed bullish: 1 bullish, 0 neutral, and 0 bearish.

Recent TGTX coverage spans financial news, earnings and corporate actions.

What's driving TGTX

AlphAI scores every news story that mentions TGTX with an AI model for sentiment and relevance, and aggregates insider trades from TG THERAPEUTICS, INC.'s SEC EDGAR Form 4 filings. Figures refresh continuously.

News on $TGTX

Score

TG Therapeutics: 3 Key Takeaways for Long-Term Investors

TG Therapeutics' executives expressed confidence in BRIUMVI's long-term growth potential, citing expanded patient reach, existing commercial infrastructure, and a long patent runway. The company has $557 million in cash and investments, with patent protection extending into the mid-2040s, providing financial flexibility for pipeline progress and share repurchases.

TG Therapeutics (TGTX) Q3 2026 Earnings Call Transcript

TG Therapeutics (TGTX) reported $1B annual revenue, highlighting progress with BRIUMVI. Key updates include seven-year clinical data, real-world evidence, and potential approvals for simplified IV dosing and self-administered subcutaneous BRIUMVI by 2028. The company also presented early results for azer-cel in progressive MS, aiming to expand its MS treatment portfolio.

$TGTXHighAI 8/10Earnings

TG Therapeutics Reports Third Quarter 2026 Financial Results and Raises Full-Year Revenue Guidance

TG THERAPEUTICS, INC. (TGTX) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 TG Therapeutics Reports Third Quarter 2026 Financial Results and Raises Full-Year Revenue Guidance Raises full-year 2026 total global revenue guidance to approximately $1 billion, from approximately $950 million Raises full-year 2026 BRIUMVI U.S. net product revenue

Report: 2026 Patient Support Awards Name Leaders in Large, Small Pharma

Nuvera, an Inizio Engage brand, announced winners of its 2026 Best-in-Class Patient Support Program Awards, with AbbVie, Sanofi/Regeneron, Pfizer, and Genentech among the top large pharma companies across various therapeutic areas. Rankings are based on feedback from over 2,300 physicians and healthcare staff. Winners will be recognized at the Informa Patient Pathways Congress in November. Nuvera also noted the increasing role of AI in patient support programs.

What iShares Trust (IJT) Sold: Viasat Leads on Oct. 26

iShares Trust (IJT) reported $148.6M net outflow on Oct. 26, selling $1.8M each of VSAT, PTGX, and RHP. IJT holds 345 stocks, with top sectors being Technology, Industrials, and Healthcare. The fund's top holdings include VSAT, PTGX, and RHP, each at around 1.11%. IJT has a P/E of 19.24, P/B of 3.01, and a YTD return of 16.42%.

$TGTXHighAI 8/10

TG Therapeutics (TGTX) Reports 7-Year BRIUMVI Data, SC/IV Dosing Updates, CAR-T MS Readout

TG Therapeutics (TGTX) announced seven-year data for BRIUMVI, Phase 3 dosing results, and Phase 1 subcutaneous data. The company also shared real-world updates and initial Phase 1 results for azer-cel in PPMS. These updates may support BRIUMVI's lifecycle and early pipeline options in MS, but larger catalysts will require further peer-reviewed results or regulatory filings.

Related tickers